GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Konruns Pharmaceutical Co Ltd (SHSE:603590) » Definitions » Forward PE Ratio

Beijing Konruns Pharmaceutical Co (SHSE:603590) Forward PE Ratio : 0.00 (As of Jun. 10, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Beijing Konruns Pharmaceutical Co Forward PE Ratio?

Beijing Konruns Pharmaceutical Co's Forward PE Ratio for today is 0.00.

Beijing Konruns Pharmaceutical Co's PE Ratio without NRI for today is 21.99.

Beijing Konruns Pharmaceutical Co's PE Ratio for today is 24.13.


Beijing Konruns Pharmaceutical Co Forward PE Ratio Historical Data

The historical data trend for Beijing Konruns Pharmaceutical Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Konruns Pharmaceutical Co Forward PE Ratio Chart

Beijing Konruns Pharmaceutical Co Annual Data
Trend
Forward PE Ratio

Beijing Konruns Pharmaceutical Co Quarterly Data
Forward PE Ratio

Competitive Comparison of Beijing Konruns Pharmaceutical Co's Forward PE Ratio

For the Biotechnology subindustry, Beijing Konruns Pharmaceutical Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Konruns Pharmaceutical Co's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Konruns Pharmaceutical Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Beijing Konruns Pharmaceutical Co's Forward PE Ratio falls into.



Beijing Konruns Pharmaceutical Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Beijing Konruns Pharmaceutical Co  (SHSE:603590) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Beijing Konruns Pharmaceutical Co Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Beijing Konruns Pharmaceutical Co's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Konruns Pharmaceutical Co (SHSE:603590) Business Description

Traded in Other Exchanges
N/A
Address
No. 11 Xingsheng South Road, Economic Development Zone, Miyun District, Beijing, CHN
Beijing Konruns Pharmaceutical Co Ltd is a Chinese pharmaceutical company. It is engaged in the research and development of innovative drugs, and is oriented to clinical needs.
Executives
Feng Zhang Zheng Director

Beijing Konruns Pharmaceutical Co (SHSE:603590) Headlines

No Headlines